Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928271 | 0.78 | OPRM1 (0.39) | OPRM1OPRL1PLG | |
| SCHEMBL4421699 | 0.76 | OPRM1 (0.40) | OPRM1OPRL1GRM5OPRK1 | |
| SCHEMBL23806264 | 0.74 | GRM5 (0.41) | OPRM1OPRL1GRM5 | |
| SCHEMBL13380554 | 0.74 | OPRM1 (0.64) | OPRM1OPRL1GRM5PLG | |
| SCHEMBL13380624 | 0.74 | OPRM1 (0.64) | OPRM1OPRL1GRM5PLG | |
| SCHEMBL8224275 | 0.72 | OPRM1 (0.47) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1930456 | 0.71 | OPRM1 (0.52) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3409090 | 0.70 | OPRM1 (0.35) | OPRM1OPRL1OPRK1 | |
| SCHEMBL24832949 | 0.70 | GRM5 (0.39) | GRM5 | |
| SCHEMBL1929418 | 0.68 | OPRM1 (0.43) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-2035411-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRL1 2/4885GRM5 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.